Patents by Inventor Andreas Vestermark

Andreas Vestermark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal modifications of elobixibat
    Patent number: 9745276
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: August 29, 2017
    Assignee: Elobix AB
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
  • Crystal modifications of elobixibat
    Patent number: 9701649
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: July 11, 2017
    Assignee: Elobix AB
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
  • CRYSTAL MODIFICATIONS OF ELOBIXIBAT
    Publication number: 20160237049
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
  • CRYSTAL MODIFICATIONS OF ELOBIXIBAT
    Publication number: 20160229822
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 11, 2016
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
  • Crystal modifications of elobixibat
    Patent number: 9409875
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: August 9, 2016
    Assignee: Elobix AB
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen
  • CRYSTAL MODIFICATIONS OF ELOBIXIBAT
    Publication number: 20160039777
    Abstract: The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 11, 2016
    Inventors: Martin Bohlin, Erica Tjerneld, Andreas Vestermark, Ingvar Ymen